Alzheimer's disease/neuropharmacology

Lars Nilsson<br>Group leader
Lars Nilsson
Group leader

Research aims
The prevalence of neurodegenerative disorders is anticipated to increase due to an aging population. In Alzheimer’s disease, the most common age-related neurodegenerative disorder, there appears to be an imbalance in the production and clearance amyloid-β and tau leading to the accumulation of aggregates and proteinaceous deposits in brain. New genetics point to the importance of mechanisms of neuroinflammation. Better understanding of pathogenic processes resulting in neurodegeneration is crucial to the identification of viable drug targets. New ways to predict drug-efficacy in an animal model and/or in small patient cohorts with biomarkers is also much needed.   

Current projects

  • Impact of innate immunity in Alzheimer’s disease
  • Role of heparan sulfate proteoglycans in amyloid formation

Contact information:
Group leader Professor Lars Nilsson Department of Pharmacology University Oslo/Oslo University Hospital Postboks 1057 Blindern NO-0316 Oslo, Norway, Tel: +47 22840221 Fax: +47 22840202 E-mail: